CDTX
Cidara Therapeutics Inc.
Price performance
Jan 8, 2026About
Company activity
30 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 01/07 | CDTX | 8-K | Cidara Therapeutics Merger with Merck Sharp & Dohme LLC Complete | — | — | — |
| 11/14/25 | CDTX | 8-K | Merck to Acquire Cidara Therapeutics for $9.2 Billion | — | — | — |
| 11/06/25 | CDTX | 8-K | Cidara Therapeutics Reports Q3 2025 Financial Results and Corporate Update | — | — | — |
| 10/03/25 | CDTX | 8-K | Cidara Therapeutics Signs Agreement with BARDA for CD388 Development | — | — | — |
| 09/24/25 | CDTX | 8-K | Cidara Therapeutics Expands Phase 3 Trial for CD388 Based on FDA Feedback | — | — | — |
| 08/07/25 | CDTX | 8-K | Cidara Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates | — | — | — |
| 06/25/25 | CDTX | 8-K | Cidara Therapeutics Announces Underwritten Public Offering of Common Stock | — | — | — |
| 06/24/25 | CDTX | 8-K | Cidara Therapeutics Terminates ATM Prospectus | — | — | — |
| 06/23/25 | CDTX | 8-K | Cidara Therapeutics Announces Positive Topline Results for CD388 in Phase 2b Trial | — | — | — |
| 06/20/25 | CDTX | 8-K | Cidara Therapeutics Increases Authorized Share Count | — | — | — |
| 05/08/25 | CDTX | 8-K | Cidara Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | — | — | — |
| 03/06/25 | CDTX | 8-K | Cidara Therapeutics Reports Full Year 2024 Financial Results and Business Updates | — | — | — |
| 02/18/25 | CDTX | 8-K | Cidara Therapeutics Announces CFO Transition | — | — | — |
| 01/07/25 | CDTX | 8-K | Board Changes at Cidara Therapeutics | — | — | — |
| 11/26/24 | CDTX | 8-K | Cidara Therapeutics Announces $105 Million Private Placement | — | — | — |
| 11/07/24 | CDTX | 8-K | Cidara Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates | — | — | — |
| 09/23/24 | CDTX | 8-K | Cidara Therapeutics Initiates Phase 2b NAVIGATE Trial for CD388 Influenza Prophylaxis | — | — | — |
| 09/12/24 | CDTX | 8-K | Cidara Therapeutics Announces Workforce Reduction and Clinical Trial Plans | — | — | — |
| 08/13/24 | CDTX | 8-K | Cidara Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Updates | — | — | — |
| 07/18/24 | CDTX | 8-K | Cidara Therapeutics, Inc. Announces Approval of 2024 Equity Incentive Plan and Amendments at Annual Meeting | — | — | — |
| 05/20/24 | CDTX | 8-K | Cidara Therapeutics Announces 2023 Executive Bonus Determinations | — | — | — |
| 05/15/24 | CDTX | 8-K | Cidara Therapeutics Reports Q1 2024 Financial Results and Key Corporate Updates | — | — | — |
| 05/03/24 | CDTX | 8-K | Cidara Therapeutics Updates Investor Presentation | — | — | — |
| 04/29/24 | CDTX | 8-K | Cidara Therapeutics Sells Rezafungin Acetate Assets to NAPP | — | — | — |
| 04/24/24 | CDTX | 8-K | Cidara Therapeutics Announces Licensing Agreement with Janssen and Private Placement | — | — | — |
| 04/24/24 | CDTX | 8-K | Cidara Therapeutics Announces Sale of Rezafungin Acetate Assets to NAPP | — | — | — |
| 04/22/24 | CDTX | 8-K | Cidara Therapeutics Announces Reverse Stock Split and Reports Q4 2023 Financial Results | — | — | — |
| 04/16/24 | CDTX | 8-K | Cidara Therapeutics Announces Restatement of Prior Financial Statements Due to Indirect Tax Accounting Error | — | — | — |
| 04/05/24 | CDTX | 8-K | Cidara Therapeutics, Inc. Approves Reverse Stock Split | — | — | — |
| 02/09/24 | CDTX | 8-K | Nasdaq Grants Listing Continuation to Cidara Therapeutics | — | — | — |
CDTX filing record
Cidara Therapeutics Inc. (CDTX): 30 8-K filings summarized, the most recent on Jan 7, 2026.
What the 8-K filings said
- Jan 7, 2026 · high impact
Cidara Therapeutics, Inc. has completed its merger with Merck Sharp & Dohme LLC, becoming a wholly owned subsidiary. The merger was finalized on January 7, 2026, following a tender offer that resulted in 88.3% of Cidara's shares being validly tendered. As part of the merger agreement, Cidara's equity incentive plans…
Cidara Therapeutics Merger with Merck Sharp & Dohme LLC Complete - Nov 14, 2025 · high impact
Cidara Therapeutics, Inc. has entered into a definitive merger agreement with Merck Sharp & Dohme LLC, a subsidiary of Merck, for an acquisition price of $221.50 per share in cash, totaling approximately $9.2 billion. The transaction, which has been approved by both companies' Boards of Directors, is expected to close…
Merck to Acquire Cidara Therapeutics for $9.2 Billion - Nov 6, 2025 · low impact
Cidara Therapeutics, Inc. reported financial results for the third quarter of 2025 and provided updates on its non-vaccine influenza preventative therapeutic, CD388. The company's cash balance increased significantly to $476.5 million. Key highlights include the enrollment and dosing of the first patients in the Phase…
Cidara Therapeutics Reports Q3 2025 Financial Results and Corporate Update - Oct 3, 2025 · medium impact
On September 30, 2025, Cidara Therapeutics, Inc. entered into a significant agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support the expanded manufacturing and clinical development of CD388, a non-vaccine influenza preventative therapeutic. The BARDA Agreement includes potential…
Cidara Therapeutics Signs Agreement with BARDA for CD388 Development - Sep 24, 2025 · high impact
On September 24, 2025, Cidara Therapeutics, Inc. announced significant updates to its planned Phase 3 registrational trial of CD388, following feedback from the U.S. FDA. The study population will be expanded to include adults over 65 years of age with no specific co-morbidities in addition to subjects over 12 years…
Cidara Therapeutics Expands Phase 3 Trial for CD388 Based on FDA Feedback
SEC filings in the last five years
- 60 Form 8-K
- 13 Form 10-Q
- 4 Form 10-K
- 1 Form 8-K/A